Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$1.89BAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John V. Oyler
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12,000
- Beta
- 0.52
- Country
- CH
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 6.92
Financials
Revenue
$1.89B+758.2%Net Income
$384.71MEBITDA
$452.77MFree Cash Flow
$473.53MEPS (diluted)
$3.25Shares Outstanding (diluted)
117.30M+195.6%Operating Expenses
$1.25BCash & Debt
$5.78BRevenue by Segment (annual)
$6.79BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.34B | $286.93M | $2.63 |
| 2024 | $3.81B | $-644.79M | $-6.12 |
| 2023 | $2.46B | $-881.71M | $-8.45 |
| 2022 | $1.42B | $-2.00B | $-19.37 |
| 2021 | $1.18B | $-1.46B | $-15.21 |
| 2020 | $308.87M | $-1.62B | $-19.11 |
| 2019 | $428.21M | $-948.63M | $-15.86 |
| 2018 | $198.22M | $-673.77M | $-12.09 |
| 2017 | $238.39M | $-93.11M | $-2.21 |
| 2016 | $1.07M | $-119.22M | $-3.90 |
| 2015 | $8.82M | $-57.10M | $-1.82 |
| 2014 | $13.04M | $-18.28M | $-0.35 |
| 2013 | $11.15M | $-7.49M | $-1.43 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.87
- Implied price
- $69.58
- Return from $390.94
- -29.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $34.59 — -91.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -40.8% | -38.0% | -35.7% | -33.7% | -31.9% |
| 3.0% | -37.7% | -34.9% | -32.5% | -30.4% | -28.5% |
| 8.0% | -34.7% | -31.7% | -29.2% | -27.0% | -25.0% |
| 13.0% | -31.7% | -28.6% | -25.9% | -23.6% | -21.5% |
| 18.0% | -28.7% | -25.4% | -22.6% | -20.2% | -18.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
10-80.00%Social Signal Score
Mentions (14)
- Newsmarketbeat.com·16d ago·Negative
BeOne Medicines Q3 Earnings Call Highlights BeOne Medicines NASDAQ: ONC raised its 2026 revenue and operating income forecasts after third-quarter sales of its cancer drug BRUKINSA topped $1 billion in the United States for the first time.
View source ↗ - Newszacks.com·17d ago·Negative
Compared to Estimates, BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: A Look at Key Metrics Although the revenue and EPS for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
BeOne Medicines AG (ONC) Q3 2026 Earnings Call Transcript BeOne Medicines AG ( ONC ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Daniel Maller - Vice President of Investor Relations John Oyler - Co-Founder, Executive Chairman & CEO Aaron Rosenberg - Chief Financial Officer Lai Wang Amit Agarwal - Chief Medical Officer of Hematology Mark Lanasa - Senior VP & Chief Medical Officer for Solid Tumors Matthew Shaulis - General Manager of North America Xiaobin Wu Conference …
View source ↗ - Newsbusinesswire.com·17d ago·Neutral
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematol…
View source ↗ - Newszacks.com·19d ago·Negative
Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key Metrics Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Sponsored ADR (ONC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
View source ↗ - Newsbusinesswire.com·29d ago·Neutral
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026 SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast…
View source ↗ - Newsbusinesswire.com·30d ago·Neutral
…e Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab)…
View source ↗ - Newsbusinesswire.com·31d ago·Neutral
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5 SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed fr…
View source ↗ - Newszacks.com·38d ago·Positive
All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong Buy BeOne Medicines Ltd. - Sponsored ADR (ONC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
View source ↗ - Newsinvestors.com·52d ago·Negative
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2 billion in sales in the second quarter.
View source ↗ - Newsbusinesswire.com·83d ago·Positive
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver …
View source ↗ - Newsbusinesswire.com·83d ago·Neutral
…ces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as fi…
View source ↗ - Newszacks.com·87d ago·Neutral
BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy? Does BeOne Medicines Ltd. - Sponsored ADR (ONC) have what it takes to be a top stock pick for momentum investors?
View source ↗ - Newsbusinesswire.com·96d ago·Neutral
…o Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand acc…
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $3.99 per share
Typical surprise +63.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$4.59 vs $2.34beat
- Wed, Aug 5$2.05 vs $1.63beat
- Wed, May 6$1.96 vs $0.73beat
- Thu, Feb 26$0.58 vs $1.60miss
- Thu, Nov 6$1.09 vs $0.72beat
- Wed, Aug 6$0.84 vs $0.48beat
Estimates and results for ONC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ONC officers and directors.
- Bought
- —
- Sold
- $148.4m
0 trades
71 trades
- Ball Titus B.sold
- Ball Titus B.sold
- Lee Chan Henrysold
- Lee Chan Henrysold
- Wang Xiaodongsold
- Wang Xiaodongsold
- Wang Xiaodongsold
- Wang Xiaodongsold
29 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ONC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
